UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019835
Receipt number R000022911
Scientific Title A randomised controlled trial to evaluate the efficacy of vonoprazan for artificial ulcer healing after gastric endoscopic submucosal dissection
Date of disclosure of the study information 2015/11/18
Last modified on 2019/12/03 11:44:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomised controlled trial to evaluate the efficacy of vonoprazan for artificial ulcer healing after gastric endoscopic submucosal dissection

Acronym

The efficacy of vonoprazan for ESD-induced ulcer

Scientific Title

A randomised controlled trial to evaluate the efficacy of vonoprazan for artificial ulcer healing after gastric endoscopic submucosal dissection

Scientific Title:Acronym

The efficacy of vonoprazan for ESD-induced ulcer

Region

Japan


Condition

Condition

Gastric ulcer

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

compare the efficacy of the combined therapy with vonoprazan and rebamipide to lansoprazole and rebamipide for artificial gastric ulcer after endoscopic submucosal dissection

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Cure rates of gastric ulcer at 4 weeks after treatment

Key secondary outcomes

Cure rates of gastric ulcer at 8 weeks after treatment, reduction rates of gastric ulcer at 4 and 8 weeks after treatment, incidence rate of delayed bleeding


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

vonoprazan 20mg/day for 4 to 8 weeks p.o.
rebamipide 300mg/day for 4 to 8 weeks p.o.

Interventions/Control_2

lansoprazole 30mg/day for 4 to 8 weeks p.o.
rebamipide 300mg/day for 4 to 8 weeks p.o.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Patients aged 20 to 89 who scheduled for ESD for gastric adenoma or early cancer

Key exclusion criteria

Patients with
1)the history of surgery for upper GI
2)concomitant administration of anticoagulants
3)concomitant administration of PPI
4)the history of radiotherapy or chemotherapy within 3 months
5)gastric hyperacidity such as Zollinger-Ellison syndorome
6)allergy to PPI or rebamipide

Target sample size

130


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Junichi Akiyama

Organization

National Center for Global Health and Medicine

Division name

Gastroenterological medicine

Zip code


Address

1-21-1 toyama,shinjyuku,tokyo

TEL

03-3202-7181

Email

jakiyama.ncgm@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Kazuhiro Watanabe

Organization

National Center for Global Health and Medicine

Division name

Gastroenterological medicine

Zip code


Address

1-21-1 toyama,shinjyuku,tokyo

TEL

03-3202-7181

Homepage URL


Email

kazuw0229@gmail.com


Sponsor or person

Institute

National Center for Global Health and Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立国際医療研究センター


Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 07 Month 13 Day

Date of IRB

2015 Year 07 Month 13 Day

Anticipated trial start date

2015 Year 08 Month 01 Day

Last follow-up date

2019 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 11 Month 18 Day

Last modified on

2019 Year 12 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022911


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name